Logo image of SGTX

SIGILON THERAPEUTICS INC (SGTX) Stock Fundamental Analysis

NASDAQ:SGTX - Nasdaq - US82657L2060 - Common Stock - Currency: USD

22.47  -0.59 (-2.56%)

After market: 23 +0.53 (+2.36%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to SGTX. SGTX was compared to 555 industry peers in the Biotechnology industry. SGTX has a bad profitability rating. Also its financial health evaluation is rather negative. SGTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SGTX had negative earnings in the past year.
SGTX had a negative operating cash flow in the past year.
SGTX had negative earnings in each of the past 5 years.
In the past 5 years SGTX reported 4 times negative operating cash flow.
SGTX Yearly Net Income VS EBIT VS OCF VS FCFSGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 20M -20M -40M -60M -80M

1.2 Ratios

The profitability ratios for SGTX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SGTX Yearly ROA, ROE, ROICSGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -500 -1K -1.5K -2K -2.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SGTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGTX Yearly Profit, Operating, Gross MarginsSGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -200 -400 -600 -800

More info and screens

2

2. Health

2.1 Basic Checks

SGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SGTX has more shares outstanding
SGTX has a worse debt/assets ratio than last year.
SGTX Yearly Shares OutstandingSGTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M
SGTX Yearly Total Debt VS Total AssetsSGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

SGTX has an Altman-Z score of -4.91. This is a bad value and indicates that SGTX is not financially healthy and even has some risk of bankruptcy.
SGTX has a worse Altman-Z score (-4.91) than 68.20% of its industry peers.
SGTX has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
SGTX has a worse Debt to Equity ratio (0.31) than 73.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -4.91
ROIC/WACCN/A
WACC9.94%
SGTX Yearly LT Debt VS Equity VS FCFSGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

SGTX has a Current Ratio of 2.23. This indicates that SGTX is financially healthy and has no problem in meeting its short term obligations.
SGTX's Current ratio of 2.23 is on the low side compared to the rest of the industry. SGTX is outperformed by 80.27% of its industry peers.
SGTX has a Quick Ratio of 2.23. This indicates that SGTX is financially healthy and has no problem in meeting its short term obligations.
SGTX has a Quick ratio of 2.23. This is in the lower half of the industry: SGTX underperforms 78.57% of its industry peers.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 2.23
SGTX Yearly Current Assets VS Current LiabilitesSGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for SGTX have decreased strongly by -327.88% in the last year.
The Revenue has grown by 49.27% in the past year. This is a very strong growth!
Measured over the past years, SGTX shows a decrease in Revenue. The Revenue has been decreasing by -2.95% on average per year.
EPS 1Y (TTM)-327.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-595.35%
Revenue 1Y (TTM)49.27%
Revenue growth 3Y-2.95%
Revenue growth 5YN/A
Sales Q2Q%53.49%

3.2 Future

The Earnings Per Share is expected to grow by 13.31% on average over the next years. This is quite good.
The Revenue is expected to decrease by -0.28% on average over the next years.
EPS Next Y-34.47%
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%
EPS Next 5Y13.31%
Revenue Next Year19.62%
Revenue Next 2Y10.18%
Revenue Next 3Y6.68%
Revenue Next 5Y-0.28%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SGTX Yearly Revenue VS EstimatesSGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5M 10M 15M
SGTX Yearly EPS VS EstimatesSGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGTX Price Earnings VS Forward Price EarningsSGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGTX Per share dataSGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

SGTX's earnings are expected to decrease with -16.93% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SIGILON THERAPEUTICS INC

NASDAQ:SGTX (8/10/2023, 8:02:09 PM)

After market: 23 +0.53 (+2.36%)

22.47

-0.59 (-2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-02 2023-08-02/amc
Earnings (Next)11-08 2023-11-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners80.43%
Ins Owner Change0%
Market Cap56.50M
Analysts80
Price Target48.28 (114.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.03%
Min EPS beat(2)0.52%
Max EPS beat(2)45.53%
EPS beat(4)4
Avg EPS beat(4)21.01%
Min EPS beat(4)0.26%
Max EPS beat(4)45.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)25.42%
Min Revenue beat(2)-2.79%
Max Revenue beat(2)53.64%
Revenue beat(4)3
Avg Revenue beat(4)32.66%
Min Revenue beat(4)-2.79%
Max Revenue beat(4)66.75%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1013.72%
EPS NQ rev (1m)0.21%
EPS NQ rev (3m)-1950%
EPS NY rev (1m)-1057.2%
EPS NY rev (3m)-1057.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)37.1%
Revenue NY rev (1m)27.67%
Revenue NY rev (3m)27.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.86
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 1.7
EV/EBITDA N/A
EPS(TTM)-9.67
EYN/A
EPS(NY)-13.12
Fwd EYN/A
FCF(TTM)-17.45
FCFYN/A
OCF(TTM)-17.26
OCFYN/A
SpS5.82
BVpS13.24
TBVpS13.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 2.23
Altman-Z -4.91
F-Score2
WACC9.94%
ROIC/WACCN/A
Cap/Depr(3y)106.78%
Cap/Depr(5y)188.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-327.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-595.35%
EPS Next Y-34.47%
EPS Next 2Y-35.84%
EPS Next 3Y-16.93%
EPS Next 5Y13.31%
Revenue 1Y (TTM)49.27%
Revenue growth 3Y-2.95%
Revenue growth 5YN/A
Sales Q2Q%53.49%
Revenue Next Year19.62%
Revenue Next 2Y10.18%
Revenue Next 3Y6.68%
Revenue Next 5Y-0.28%
EBIT growth 1Y46.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.02%
EBIT Next 3Y8.16%
EBIT Next 5YN/A
FCF growth 1Y37.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.23%
OCF growth 3YN/A
OCF growth 5YN/A